| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.0034 | 1 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.0025 | 1 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.0021 | 1 |